For most of his adult life, Aaron Presley, age 34, felt like a husk of a person, a piece of "garbage."
Exploring the companies and themes that make up this emerging and exciting new sector
Former GOP Congresswoman Touts Psilocybin As Treatment For Alcoholism
A former Republican congresswoman is touting the therapeutic benefits of psychedelics, sharing the story of how a close family friend was able to recover from alcoholism with the help of psilocybin.
Small Pharma Successfully Completes Phase I Clinical Trial Of DMT In Combination With Supportive Psychotherapy
Small Pharma shows DMT to be well-tolerated and safe for the study population as it moves forward toward a Phase IIa clinical trial.
New neuroscience research suggests the cerebral cortex acts as the brain’s hourglass
No one can stay awake forever. While we’re awake, our need for sleep gradually increases.
Study on MDMA for Traumatic Brain Injury Boosted By $1.5M Donation
Wesana Health committed to fund a MAPS study on MDMA for traumatic brain injury.
The Two-Pronged Psychedelics Solution To The Opioid Crisis
Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.
AdvisorShares Launches Psychedelics ETF (Ticker: PSIL)
AdvisorShares' new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol "PSIL") with a focus on small-cap psychedelic stocks.
California Activists Cleared To Collect Signatures For Psilocybin Legalization Ballot Initiative
California activists are now cleared to begin collecting signatures for an initiative to legalize psilocybin mushrooms in the state.
House Could Vote On Psychedelics Research For Military And Marijuana Banking As Part Of Defense Bill
House lawmakers have introduced a series of drug policy-related amendments to defense legislation, including proposals to facilitate research on the benefits of psychedelics for active duty military personnel and to protect banks that service state-legal marijuana businesses.
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.
Detroit Voters Will Decide On Psychedelics Decriminalization Ballot Measure In November
Detroit could become one of the next Michigan cities to decriminalize psychedelics, with the reform proposal making the local ballot for this November.